SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Vyndaqel

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed since May 2019.
Why 4/10
Vyndaqel/Vyndamax is already approved and commercialized with no pending PDUFA, pivotal readout, or Advisory Committee date in the next 12 months. The defining binary catalyst (FDA approval) passed in 2019. While it is a major revenue contributor ($6.38B in 2025), Pfizer is a large, diversified company, so this single drug does not drive a make-or-break binary for the stock.
Actionable Insight NEUTRAL

Vyndaqel/Vyndamax has no upcoming binary regulatory catalyst; the next key events to watch are quarterly sales trends as competition from BridgeBio's Attruby and Alnylam's Amvuttra intensifies, and any further patent litigation outcomes. For Pfizer, a diversified pharma giant, this drug is one of several growth drivers and not a single-point-of-failure binary.

Price Chart

Loading chart...

Executive Summary

Vyndaqel (tafamidis meglumine) and its sister brand Vyndamax (tafamidis) are Pfizer's blockbuster treatments for transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM), a rare and fatal heart condition. FDA-approved in May 2019 as the first therapy for ATTR-CM, the drug stabilizes the transthyretin protein to prevent amyloid buildup in the heart. The franchise generated $6.38 billion in 2025 revenue (up 17% year-over-year), making it one of Pfizer's most important non-COVID products. Pfizer settled patent litigation with generic manufacturers in April 2026, extending U.S. exclusivity to June 2031. However, competition is intensifying: BridgeBio's Attruby (acoramidis) launched in late 2024, and Alnylam's Amvuttra (vutrisiran) also entered the ATTR-CM market. Pfizer discontinued the original Vyndaqel formulation in the U.S. at end of 2025, consolidating around Vyndamax.

How It Works

Tafamidis is a selective stabilizer of the transthyretin (TTR) protein. In ATTR amyloidosis, the TTR protein becomes unstable and breaks apart, forming clumps called amyloid fibrils that build up in the heart and other organs, causing progressive damage. Tafamidis binds to the TTR protein and holds it together, preventing it from breaking down into these toxic clumps, which slows the progression of heart damage.

Trial Status

Vyndaqel/Vyndamax was approved by the FDA on May 3, 2019, based on the pivotal Phase 3 ATTR-ACT trial, which showed reductions in cardiovascular mortality and cardiovascular-related hospitalizations. Post-hoc analyses published in October 2026 showed continued benefit for up to 90 months of treatment. Pfizer discontinued the original Vyndaqel (20mg capsules) in the U.S. at the end of 2025, consolidating around the single-pill Vyndamax (61mg) formulation.

The Two-Sided Case

▲ Bull Case4
Vyndaqel family generated $6.38 billion in 2025 revenue, up 17% year-over-year, making it one of Pfizer's fastest-growing major products.
Patent settlements with three generic manufacturers (Dexcel, Hikma, Cipla) extended U.S. exclusivity to June 1, 2031, protecting the franchise from generic erosion through mid-2031.
Real-world data published October 2026 showed tafamidis associated with 74% lower all-cause mortality risk in ATTR-CM patients versus untreated patients, reinforcing clinical value.
ATTR-CM remains underdiagnosed, providing a large addressable patient pool for continued market expansion.
▼ Bear Case4
Competition is intensifying: BridgeBio's Attruby (acoramidis) launched in November 2024 and a September 2026 real-world study claimed it outperformed Vyndamax. Alnylam's Amvuttra (vutrisiran) also entered the ATTR-CM market.
A generic tafamidis received a positive EU regulatory opinion in July 2026, potentially pressuring international pricing and market share outside the U.S.
Pfizer discontinued the original Vyndaqel formulation in the U.S. at end of 2025, consolidating the franchise around Vyndamax, which could create transitional friction.
As a large, diversified pharma company, Pfizer's stock is not highly sensitive to Vyndaqel's performance alone; the drug is one of many products.

Upcoming Catalysts

  • No upcoming FDA regulatory decision or pivotal readout for Vyndaqel/Vyndamax is scheduled. The next catalysts are quarterly sales reports and competitive dynamics against BridgeBio's Attruby and Alnylam's Amvuttra.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 12

Hover a chip for the title
1 pfizer.com2 pfizer.com3 biospace.com4 corpdigest.com5 pharmaceutical-technology.com6 bioengineer.org7 seekingalpha.com8 medscape.com9 fiercepharma.com10 cnbc.com11 businesswire.com12 accessdata.fda.gov